Skip to content

Electrical Patient Reported Outcome of Prostate Cancer RadioTherapy

Electrical Patient Reported Outcome of Prostate Cancer RadioTherapy

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05187026
Acronym
ePRO-PCaRT
Enrollment
300
Registered
2022-01-11
Start date
2016-12-09
Completion date
2022-12-31
Last updated
2022-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

PROM, EPIC-26, electronic, questionnaire, mobile, quality of life, radiation therapy

Brief summary

This is an observational study where prostate cancer related PROMs (EPIC-26) is collected using two different methods (by paper questionnaires and electronically) and patient experience and preference is asked.

Detailed description

Prostate cancer patients that are treated with radiation therapy for local prostate cancer receive EPIC-26 before treatment and during follow-up. EPIC-26 is collected both traditionally using paper questionnaires and electronically. Patients experience and preference for these are asked.

Interventions

OTHERelectronic PROMs questionnaire

Patients are asked to complete EPIC-26 questionnaire in paper and electronically

Sponsors

Helsinki University Central Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to 100 Years

Inclusion criteria

* cT1-4N0M0, gleason 6-10, PSA \< 100, WHO ≤ 2 prostate cancer eligible for radiation therapy * willing to complete EPIC-26 questionnaires both in paper and electronically * willing to consent for the study

Exclusion criteria

* not able to complete EPIC-26 both in paper and electronically

Design outcomes

Primary

MeasureTime frameDescription
preferencethrough study completion, an average of 1 yearpatient preference for type of questionnaire (paper versus electronic)

Secondary

MeasureTime frameDescription
QoL as measured using the validated EPIC-26 questionnairethrough study completion, an average of 1 yearPatient QoL after RT (EPIC-26, scale 0-100)

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026